458 related articles for article (PubMed ID: 31617856)
1. Decision-Analytic Modeling for Time-Effectiveness of the Sequence of Induction Treatments for Moderate to Severe Plaque Psoriasis.
Zidane M; Dressler C; Gaskins M; Nast A
JAMA Dermatol; 2019 Dec; 155(12):1380-1389. PubMed ID: 31617856
[TBL] [Abstract][Full Text] [Related]
2. Cost-effectiveness of secukinumab as first biologic treatment, compared with other biologics, for moderate to severe psoriasis in Germany.
Augustin M; McBride D; Gilloteau I; O'Neill C; Neidhardt K; Graham CN
J Eur Acad Dermatol Venereol; 2018 Dec; 32(12):2191-2199. PubMed ID: 29729105
[TBL] [Abstract][Full Text] [Related]
3. Etanercept and efalizumab for the treatment of psoriasis: a systematic review.
Woolacott N; Hawkins N; Mason A; Kainth A; Khadjesari Z; Vergel YB; Misso K; Light K; Chalmers R; Sculpher M; Riemsma R
Health Technol Assess; 2006 Nov; 10(46):1-233, i-iv. PubMed ID: 17083854
[TBL] [Abstract][Full Text] [Related]
4. Cost effectiveness of biologic therapies for plaque psoriasis.
Ahn CS; Gustafson CJ; Sandoval LF; Davis SA; Feldman SR
Am J Clin Dermatol; 2013 Aug; 14(4):315-26. PubMed ID: 23696234
[TBL] [Abstract][Full Text] [Related]
5. Comparison of Health Care Costs Among Patients with Psoriasis Initiating Ixekizumab, Secukinumab, or Adalimumab.
Blauvelt A; Shi N; Zhu B; Burge R; Malatestinic WN; Lin CY; Lew CR; Zimmerman NM; Goldblum OM; Murage MJ
J Manag Care Spec Pharm; 2019 Dec; 25(12):1366-1376. PubMed ID: 31778621
[TBL] [Abstract][Full Text] [Related]
6. Brodalumab for the Treatment of Moderate-to-Severe Plaque Psoriasis: An Evidence Review Group Evaluation of a NICE Single Technology Appraisal.
Wade R; Grosso A; South E; Rothery C; Saramago P; Schmitt L; Wright K; Palmer S
Pharmacoeconomics; 2019 Feb; 37(2):131-139. PubMed ID: 30112635
[TBL] [Abstract][Full Text] [Related]
7. Greater cumulative benefits from ixekizumab versus ustekinumab treatment over 52 weeks for patients with moderate-to-severe psoriasis in a randomized, double-blinded phase 3b clinical trial.
Blauvelt A; Lomaga M; Burge R; Zhu B; Shen W; Shrom D; Dossenbach M; Pinter A
J Dermatolog Treat; 2020 Mar; 31(2):141-146. PubMed ID: 30799638
[No Abstract] [Full Text] [Related]
8. Quality of life outcomes in adults with moderate-to-severe plaque psoriasis treated with dimethylfumarate (DMF): a post hoc analysis of the BRIDGE study.
van de Kerkhof PCM; Loewe R; Mrowietz U; Falques M; Pau-Charles I; Szepietowski JC
J Eur Acad Dermatol Venereol; 2020 Jan; 34(1):119-126. PubMed ID: 31465585
[TBL] [Abstract][Full Text] [Related]
9. Fumaric acid esters in combination with a 6-week course of narrowband ultraviolet B provides an accelerated response compared with fumaric acid esters monotherapy in patients with moderate-to-severe plaque psoriasis: a randomized prospective clinical study.
Tzaneva S; Geroldinger A; Trattner H; Tanew A
Br J Dermatol; 2018 Mar; 178(3):682-688. PubMed ID: 29114862
[TBL] [Abstract][Full Text] [Related]
10. Cost-Effectiveness of Targeted Pharmacotherapy for Moderate to Severe Plaque Psoriasis.
Hendrix N; Ollendorf DA; Chapman RH; Loos A; Liu S; Kumar V; Linder JA; Pearson SD; Veenstra DL
J Manag Care Spec Pharm; 2018 Dec; 24(12):1210-1217. PubMed ID: 30479197
[TBL] [Abstract][Full Text] [Related]
11. Effectiveness and survival of methotrexate versus adalimumab in patients with moderate-to-severe psoriasis: a cohort study from the British Association of Dermatologists Biologics and Immunomodulators Register (BADBIR).
Alabas OA; Mason KJ; Yiu ZZN; Warren RB; Lunt M; Smith CH; Griffiths CEM;
Br J Dermatol; 2023 Aug; 189(3):271-278. PubMed ID: 37226927
[TBL] [Abstract][Full Text] [Related]
12. Sustained Psoriasis Area and Severity Index, Dermatology Life Quality Index and EuroQol-5D response of biological treatment in psoriasis: 10 years of real-world data in the Swedish National Psoriasis Register.
Hjalte F; Carlsson KS; Schmitt-Egenolf M
Br J Dermatol; 2018 Jan; 178(1):245-252. PubMed ID: 28644904
[TBL] [Abstract][Full Text] [Related]
13. Cost per additional responder for ixekizumab and other FDA-approved biologics in moderate-to-severe plaque psoriasis.
Al Sawah S; Foster SA; Burge R; Amato D; Schacht A; Zhu B; Hartz S; Leonardi C
J Med Econ; 2017 Dec; 20(12):1224-1230. PubMed ID: 28760056
[TBL] [Abstract][Full Text] [Related]
14. Comparison of the cost-effectiveness of biologic drugs used for moderate-to-severe psoriasis treatment in the United States.
Wu JJ; Feldman SR; Rastogi S; Menges B; Lingohr-Smith M; Lin J
J Dermatolog Treat; 2018 Dec; 29(8):769-774. PubMed ID: 29658383
[TBL] [Abstract][Full Text] [Related]
15. Infliximab for the treatment of adults with psoriasis.
Loveman E; Turner D; Hartwell D; Cooper K; Clegg A
Health Technol Assess; 2009 Jun; 13 Suppl 1():55-60. PubMed ID: 19567215
[TBL] [Abstract][Full Text] [Related]
16. Economic evaluation of systemic therapies for moderate to severe psoriasis.
Sizto S; Bansback N; Feldman SR; Willian MK; Anis AH
Br J Dermatol; 2009 Jun; 160(6):1264-72. PubMed ID: 19120346
[TBL] [Abstract][Full Text] [Related]
17. Health economic analyses of psoriasis management: a systematic literature search.
Gutknecht M; Krensel M; Augustin M
Arch Dermatol Res; 2016 Nov; 308(9):601-616. PubMed ID: 27435415
[TBL] [Abstract][Full Text] [Related]
18. Cost-effectiveness of systemic treatments for moderate-to-severe psoriasis in the German health care setting.
Küster D; Nast A; Gerdes S; Weberschock T; Wozel G; Gutknecht M; Schmitt J
Arch Dermatol Res; 2016 May; 308(4):249-61. PubMed ID: 26961372
[TBL] [Abstract][Full Text] [Related]
19. Improvement in Patient-Reported Outcomes (Dermatology Life Quality Index and the Psoriasis Symptoms and Signs Diary) with Guselkumab in Moderate-to-Severe Plaque Psoriasis: Results from the Phase III VOYAGE 1 and VOYAGE 2 Studies.
Armstrong AW; Reich K; Foley P; Han C; Song M; Shen YK; You Y; Papp KA
Am J Clin Dermatol; 2019 Feb; 20(1):155-164. PubMed ID: 30417277
[TBL] [Abstract][Full Text] [Related]
20. Economic Evaluation of Selected Interleukin Inhibitors Versus Methotrexate for Moderate-to-Severe Plaque Psoriasis From the Philippine Payer Perspective.
Kimwell MJM; de Guzman DC; Onda AJM; Dofitas BL; Frez MLF; Mendoza CG; Rivera FD; Almirol BJQ; Malaluan MJQ; Guce K
Value Health Reg Issues; 2023 Mar; 34():100-107. PubMed ID: 36638606
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
